Buyout (LBO, MBO, MBI) • Life Science

Curewell Capital Acquires Wilmington PharmaTech

On October 21, 2025, growth capital firm Curewell Capital acquired life science company Wilmington PharmaTech

Acquisition Context

This is Curewell Capital’s 1st transaction in the Life Science sector.
This is Curewell Capital’s 1st transaction in the United States.
This is Curewell Capital’s 1st transaction in Delaware.

Explore All 460 Buyout (LBO, MBO, MBI) Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 21, 2025
Target	Wilmington PharmaTech
Sector	Life Science
Buyer(s)	Curewell Capital
Deal Type	Buyout (LBO, MBO, MBI)
Advisor(s)	Potter Anderson & Corroon (Legal)

Target Company

Wilmington PharmaTech

Newark, Delaware, United States

Wilmington PharmaTech is a specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing. It operates two adjacent state-of-the-art facilities with extensive cGMP manufacturing capabilities, including dedicated high potency API (HPAPI) suites, as well as registered starting material (RSM) support and R&D facility in Suzhou, China. Wilmington PharmaTech is based in Newark, Delaware.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer